32.72
-1.54 (-4.50%)
| Previous Close | 34.26 |
| Open | 34.00 |
| Volume | 1,101,155 |
| Avg. Volume (3M) | 1,427,720 |
| Market Cap | 1,828,347,520 |
| Price / Sales | 5.27 |
| Price / Book | 4.22 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Profit Margin | -36.20% |
| Operating Margin (TTM) | -39.67% |
| Diluted EPS (TTM) | -1.69 |
| Quarterly Revenue Growth (YOY) | 55.30% |
| Total Debt/Equity (MRQ) | 21.02% |
| Current Ratio (MRQ) | 8.95 |
| Operating Cash Flow (TTM) | -83.91 M |
| Levered Free Cash Flow (TTM) | -58.77 M |
| Return on Assets (TTM) | -13.36% |
| Return on Equity (TTM) | -27.62% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | PROCEPT BioRobotics Corporation | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 1.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -2.5 |
| Average | 1.13 |
|
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 4.22% |
| % Held by Institutions | 93.06% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Westfield Capital Management Co Lp | 30 Sep 2025 | 1,970,147 |
| Champlain Investment Partners, Llc | 30 Sep 2025 | 1,437,897 |
| Artisan Partners Limited Partnership | 30 Sep 2025 | 1,365,099 |
| Chicago Capital, Llc | 31 Dec 2025 | 1,190,995 |
| Axa Investment Managers S.A. | 30 Sep 2025 | 1,109,870 |
| Bnp Paribas Asset Management Holding S.A. | 30 Sep 2025 | 1,092,260 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 62.00 (UBS, 89.49%) | Buy |
| Median | 49.00 (49.76%) | |
| Low | 38.00 (B of A Securities, 16.14%) | Hold |
| Average | 49.50 (51.28%) | |
| Total | 3 Buy, 1 Hold | |
| Avg. Price @ Call | 33.07 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Truist Securities | 18 Dec 2025 | 47.00 (43.64%) | Buy | 32.73 |
| UBS | 12 Dec 2025 | 62.00 (89.49%) | Buy | 35.99 |
| B of A Securities | 08 Dec 2025 | 38.00 (16.14%) | Hold | 34.03 |
| Morgan Stanley | 02 Dec 2025 | 51.00 (55.87%) | Buy | 29.53 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 04 Feb 2026 | Announcement | PROCEPT BioRobotics® to Attend the TD Cowen 46th Annual Health Care Conference and the 2026 Leerink Global Healthcare Conference |
| 26 Jan 2026 | Announcement | PROCEPT BioRobotics® to Host 4Q25 Earnings Conference Call on February 24, 2026, and Investor Day on February 25, 2026, in New York City |
| 20 Nov 2025 | Announcement | PROCEPT BioRobotics® to Present at Upcoming 37th Annual Piper Sandler Healthcare Conference on December 2, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |